Adjuvant therapy for colon cancer.

摘要: In patients with colon cancer who undergo resection for potential cure, 40% to 60% have advanced locoregional disease and are classified as either stage II or III. The role of adjuvant therapy in III is well defined. results from the MOSAIC trial (Multicenter International Study Oxaliplatin/5-Fluorouracil/Leucovorin Adjuvant Treatment Colon Cancer) National Surgical Breast Bowel Project C-07 confirm a definite disease-free survival (DFS) benefit addition oxaliplatin infusional bolus 5-fluorouracil/leucovorin (5-FU/LV). Xeloda Cancer Therapy (X-ACT) showed capecitabine be equivalent clinical 5-FU/LV. However, trials irinotecan, including Leukemia Group B (CALGB 89803), Pan-European Trial Colorectal 3 (PETACC-3), French ACCORD trial, not shown significant DFS advantage. contrast, disease, small 1% 5% exists chemotherapy. Perhaps analysis molecular markers combination high-risk histopathologic features will help increase patient specificity identify subsets derive therapy. current Intergroup study stratifying based on presence microsatellite instability loss heterozygosity 18q allele us better understand risk versus observed.